ReviewVirus genes2017
Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5.
Review in Virus genes, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- An oncolytic HAdV-5 with reduced surface charge combines diminished toxicity and improved tumor targeting.Molecular therapy. Oncology · 2024Article
- Delivery of Anti-IFNAR1 shRNA to Hepatic Cells Decreases IFNAR1 Gene Expression and Improves Adenoviral Transduction and Transgene Expression.Molecular biotechnology · 2022Article
- Novel Group C Oncolytic Adenoviruses Carrying a miRNA Inhibitor Demonstrate Enhanced Oncolytic Activity In Vitro and In Vivo.Molecular cancer therapeutics · 2022Article
- Article
- Human innate lymphoid cell activation by adenoviruses is modified by host defense proteins and neutralizing antibodies.Frontiers in immunology · 2022Article
- Genetic and Chemical Capsid Modifications of Adenovirus Vectors to Modulate Vector-Host Interactions.Viruses · 2021Review
- Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer.Cancer gene therapy · 2021Review
- Identification of folate receptor α (FRα) binding oligopeptides and their evaluation for targeted virotherapy applications.Cancer gene therapy · 2020Article
- The superior role of coagulation factor FX over FVII in adenoviral-mediated innate immune induction of the hepatocyte: anClinical and experimental hepatology · 2020Article
- Adenovirus-Antibody Complexes Contributed to Lethal Systemic Inflammation in a Gene Therapy Trial.Molecular therapy : the journal of the American Society of Gene Therapy · 2020Article
- Regulation of the pyruvate metabolism node by monogene and polygene engineering of HEK-293 cells.RSC advances · 2019Article
- Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates.Virology journal · 2018Article
- Histone deacetylase inhibitor trichostatin A sensitises cisplatin-resistant ovarian cancer cells to oncolytic adenovirus.Oncotarget · 2018Article
- From Virus to vector to medicine: Foreword by guest editors.Virus genes · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, virus-based vectors, namely derivatives of the adenovirus, are frequently used in a wide variety of ex vivo or local gene therapeutic applications. However, the efficacy of virus-based vectors in systemic applications is presently still extremely limited. Complex interactions of the various vector types with the patient's organism hinder successful vector deployment. Exemplary, here we summarize barriers to systemic application of Adenovirus-based vectors leading either to acute toxic effects or rapid vector neutralization and discuss strategies to overcome these barriers aiming to develop more efficient vector types.
Indexed as
Identifiers
28755290What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.